BioCentury | Oct 26, 2018
Tools & Techniques

Deconstructing the rule of five

...accounts of successes and failures in AbbVie’s campaigns to develop bRo5 drugs against three targets: HCV NS5A protein...
BioCentury | Aug 4, 2018
Finance

Hong Kong’s first wave

...announced it submitted an NDA in China for its second HCV therapy, ravidasvir, a second-generation HCV NS5A protein...
BioCentury | Aug 3, 2018
Clinical News

Ascletis' NDA for second HCV therapy accepted in China, company begins trading in Hong Kong

...HKSE:1672) said China's State Drug Administration accepted its NDA for HCV therapy ravidasvir, a second-generation HCV NS5A protein...
...S. Eaton Ganovo, danoprevir (ASC08, ITMN-191, RG7227, r7227, ITMN B) ravidasvir (ASC16, PPI-668) Ascletis Pharma Inc. HCV NS3/4A protease complex HCV NS5A protein...
BioCentury | Aug 3, 2018
Financial News

Ascletis ends first trading week on downturn

...The country's State Drug Administration is reviewing its NDA for HCV therapy ravidasvir, a second-generation HCV NS5A protein...
BioCentury | Aug 1, 2018
Financial News

Ascletis trades flat in Hong Kong debut

...Ascletis said China's State Drug Administration accepted its NDA for HCV therapy ravidasvir, a second-generation HCV NS5A protein...
BioCentury | Jul 31, 2018
Company News

Ascletis submits Chinese NDA for second HCV therapy

...it submitted an NDA to China's State Drug Administration for HCV therapy ravidasvir. The second-generation HCV NS5A protein...
...the Gate" ). Elizabeth S. Eaton Ganovo, danoprevir (ASC08, ITMN-191, RG7227, r7227, ITMN B) ravidasvir (ASC16, PPI-668) Ascletis Pharma Inc. HCV NS5A protein...
BioCentury | Jul 27, 2018
Finance

First out the gate

...plans to submit an NDA in China this quarter for HCV drug ravidasvir, a second-generation HCV NS5A protein...
BioCentury | Jul 20, 2018
Financial News

Ascletis sets terms for Hong Kong IPO

...expects to submit an NDA in China this quarter for HCV drug ravidasvir, a second-generation HCV NS5A protein...
BioCentury | Jun 1, 2018
Clinical News

Gilead's Epclusa approved in China for HCV

...of Sovaldi sofosbuvir, a nucleotide analog HCV NS5B polymerase inhibitor; and velpatasvir (GS-5816), a pan-genotypic HCV NS5A protein...
BioCentury | May 30, 2018
Company News

Gilead's Epclusa approved in China for HCV

...of Sovaldi sofosbuvir, a nucleotide analog HCV NS5B polymerase inhibitor; and velpatasvir (GS-5816), a pan-genotypic HCV NS5A protein...
Items per page:
1 - 10 of 603